Biomarkers for allergen immunotherapy in cedar pollinosis

Allergology International

Volumn 58, Issue 2, 2009, Pages 163-170

  Fujisawa, Takao ^a   Nagao, Mizuho ^a   Hiraguchi, Yukiko ^a   Hosoki, Koa ^a   Tokuda, Reiko ^a   Usui, Satoko ^a   Masuda, Sawako ^a   Shinoda, Makito ^b   Hashiguchi, Akihiko ^b   Yamaguchi, Masao ^c  

^a MIE NATIONAL HOSPITAL   (Japan)

^b BML   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Basophils; CD203c; Cedae pollinosis; IgG4; Immunotherapy

Indexed keywords

BIOLOGICAL MARKER; CD203C ANTIGEN; CD23 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; PLACEBO; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTIGEN EXPRESSION; BASOPHIL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; JAPANESE CEDAR; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; PATIENT SELECTION; POLLEN ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TREATMENT RESPONSE; UPREGULATION;

BASOPHILS; BIOLOGICAL MARKERS; CRYPTOMERIA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RHINITIS, ALLERGIC, SEASONAL;

EID: 67651160764     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.09-RAI-0097     Document Type: Review

References (54)

1. Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A. Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005; 136:365-71.
2. Ozasa K, Hama T, Dejima K et al. A 13-year study of Japanese cedar pollinosis in Japanese schoolchildren. Allergol Int 2008; 57:175-80.
3. Nishima S, Chisaka H, Fujiwara T et al. Surveys on the prevalence of pediatric bronchial asthma in Japan: A comparison between the 1982, 1992, and 2002 surveys conducted in the same region using the same methodology. Allergol Int 2009;58:37-53.
4. Okubo K, Gotoh M. Inhibition of the antigen provoked nasal reaction by second-generation antihistamines in patients with Japanese cedar pollinosis. Allergol Int 2006;55: 261-9.
5. Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136:148-54.
6. Nishiike S, Ogino S, Irifune M et al. Measurement of quality of life during different clinical phases of Japanese cedar pollinosis. Auris Nasus Larynx 2004;31:135-9.
7. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
8. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201.
9. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
10. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-3.
11. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-8.
12. Okuda M. [A long-term follow-up study after discontinuation of immunotherapy for Japanese cedar pollinosis]. Arerugi 2006; 55:655-61.
13. Mukai K, Obata K, Tsujimura Y, Karasuyama H. New insights into the roles for basophils in acute and chronic allergy. Allergol Int 2009; 58:11-9.
14. Wilson DR, Irani AM, Walker SM et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-13.
15. Yamaguchi M, Koketsu R, Suzukawa M, Kawakami A, Iikura M. Human basophils and cytokines/chemokines. Allergol Int 2009; 58:1-10.
16. Ruedl C, Bachmann MF, Kopf M. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000;30:2056-64.
17. Von Garnier C, Astori M, Kettner A, Dufour N, Corradin G, Spertini F. In vivo kinetics of the immunoglobulin E response to allergen: bystander effect of coimmunization and relationship with anaphylaxis. Clin Exp Allergy 2002; 32:401-10.
18. Blaser K. Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Adv Exp Med Biol 1996; 409:295-303.
19. Haugaard L, Dahl R, Jacobsen L. A controlled doseresponse study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22.
20. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25.
21. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:1120-5.e2.
22. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97: 1356-65.
23. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
24. Wilson DR, Nouri-Aria KT, Walker SM et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001;107:971-6.
25. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73-9.
26. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25:195-201.
27. Ling EM, Smith T, Nguyen XD et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven Tcell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15.
28. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-9.
29. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-14.
30. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9.
31. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998;160:3555-61.
32. Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001;31:694-704.
33. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14:1666-8.
34. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+ CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
35. Kruse S, Kuehr J, Moseler M et al. Polymorphisms in the IL 18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J Allergy Clin Immunol 2003;111:117-22.
36. Reif DM, McKinney BA, Motsinger AA et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198:16-22.
37. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999;103:468-75.
38. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 2002; 105:56-62.
39. Shamji MH, Wilcock LK, Wachholz PA et al. The IgEfacilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317:71-9.
40. Klunker S, Saggar LR, Seyfert-Margolis V et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgEfacilitated allergen binding. J Allergy Clin Immunol 2007; 120:688-95.
41. Marone G, Triggiani M, de Paulis A. Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol 2005; 26:25-31.
42. Narita M, Goji J, Nakamura H, Sano K. Molecular cloning, expression, and localization of a brain-specific phosphodiesterase I/nucleotide pyrophosphatase (PD-I alpha) from rat brain. J Biol Chem 1994; 269:28235-42.
43. Buhring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004; 133:317-29.
44. Buhring HJ, Simmons PJ, Pudney M et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999; 94:2343-56.
45. Buhring HJ, Seiffert M, Giesert C et al. The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood 2001;97:3303-5.
46. Nagata K, Hirai H, Tanaka K et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999;459:195-9.
47. Hirai H, Tanaka K, Yoshie O et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193:255-61.
48. Platz IJ, Binder M, Marxer A, Lischka G, Valent P, Buhring HJ. Hymenoptera-venom-induced upregulation of the basophil activation marker ecto-nucleotide pyrophosphatase/phosphodiesterase 3 in sensitized individuals. Int Arch Allergy Immunol 2001;126:335-42.
49. Nagao M, Hiraguchi Y, Hosoki K et al. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 2008; 146(Suppl 1):47-53.
50. Nishi H, Nishimura S, Higashiura M et al. A new method for histamine release from purified peripheral blood basophils using monoclonal antibody-coated magnetic beads. J Immunol Methods 2000;240:39-46.
51. Kawakami A, Koketsu R, Suzukawa M et al. Blocking antibody is generated in allergic rhinitis patients during specific immunotherapy using standardized Japanese cedar pollen extract. Int Arch Allergy Immunol 2008;146(Suppl 1):54-60.
52. Komata T, Soderstrom L, Borres MP, Tachimoto H, Ebisawa M. The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age. J Allergy Clin Immunol 2007;119:1272-4.
53. Tokuda R, Nagao M, Hiraguchi Y et al. Antigen-induced expression of CD203c on basophils predicts IgE-mediated wheat allergy. Allergol Int 2009;58:193-9.
54. Okubo K, Gotoh M, Fujieda S et al. A randomized doubleblind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int 2008;57:265-75.